» Articles » PMID: 30740000

Screen-printed Electrode Produced by Printed-circuit Board Technology. Application to Cancer Biomarker Detection by Means of Plastic Antibody As Sensing Material

Overview
Date 2019 Feb 12
PMID 30740000
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

This research work presents, for the first time, a screen-printed electrode (SPE) made on a PCB board with silver tracks (Ag) and a three electrode configuration (AgxO-working, AgxO-counter and Ag/AgxO-reference electrodes), following the same approach as printed-circuit boards (PCBs). This low cost and disposable device was tested for screening a cancer biomarker in point-of-care. The selected biomarker was carcinogenic embryonic antigen (CEA) protein, routinely used to follow-up the progression of specific cancer diseases. The biosensor was constructed by assembling a plastic antibody on the Ag-working electrode area, acting as the biorecognition element of the device. The protein molecules that were entrapped on the polymer and positioned at the outer surface of the polypyrrole (PPy) film were removed by protease action. The imprinting effect was tested by preparing non-imprinted (NPPy) material, including only PPy as biorecognition element. Infrared and Raman studies confirmed the surface modification of these electrodes. The ability of the sensing material to rebind CEA was measured by several electrochemical techniques: cyclic voltammetry (CV), impedance spectroscopy (EIS) and square wave voltammetry (SWV). The linear response ranged from 0.05 to 1.25 against logarithm concentration. Overall, producing screen-printed electrodes by means of conventional PCB technology showed promising features, mostly regarding cost and prompt availability. The plastic antibody-based biosensor also seems to be a promising tool for screening CEA in point-of-care, with low response time, low cost, good sensitivity and high stability.

Citing Articles

Screen-Printed Electrodes as Low-Cost Sensors for Breast Cancer Biomarker Detection.

Shen Y, Sun Z, Zhao S, Chen F, Shi P, Zhao N Sensors (Basel). 2024; 24(17).

PMID: 39275589 PMC: 11398123. DOI: 10.3390/s24175679.


Tumor-Agnostic Therapy-The Final Step Forward in the Cure for Human Neoplasms?.

El-Sayed M, Bianco J, Li Y, Fabian Z Cells. 2024; 13(12.

PMID: 38920700 PMC: 11201516. DOI: 10.3390/cells13121071.


Electrochemically Synthesized MIP Sensors: Applications in Healthcare Diagnostics.

Ayankojo A, Reut J, Syritski V Biosensors (Basel). 2024; 14(2).

PMID: 38391990 PMC: 10886925. DOI: 10.3390/bios14020071.


Comparative study of electrochemical-based sensors and immunosensors in terms of advantageous features for detection of cancer biomarkers.

Ozcelikay G, Cetinkaya A, Kaya S, Ozkan S Turk J Chem. 2024; 47(5):927-943.

PMID: 38173762 PMC: 10760818. DOI: 10.55730/1300-0527.3587.


Innovative Quantification of Critical Quality Attributes.

Papamatthaiou S, Moschou D Adv Exp Med Biol. 2023; 1420:97-115.

PMID: 37258786 DOI: 10.1007/978-3-031-30040-0_7.


References
1.
Huitric E, LAUMONIER R, Burtin P, von Kleist S, Chavanel G . An optical and ultrastructural study of the localization of carcinoembryonic antigen (CEA) in normal and cancerous human rectocolonic mucosa. Lab Invest. 1976; 34(1):97-107. View

2.
Tsaltas G, Ford C, Gallant M . Demonstration of monoclonal anti-carcinoembryonic antigen (CEA) antibody internalization by electron microscopy, western blotting and radioimmunoassay. Anticancer Res. 1992; 12(6B):2133-42. View

3.
Basil C, Zhao Y, Zavaglia K, Jin P, Panelli M, Voiculescu S . Common cancer biomarkers. Cancer Res. 2006; 66(6):2953-61. DOI: 10.1158/0008-5472.CAN-05-3433. View

4.
Venisnik K, Olafsen T, Gambhir S, Wu A . Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol. 2007; 9(5):267-77. DOI: 10.1007/s11307-007-0101-8. View

5.
Soreide K, Nedrebo B, Knapp J, Glomsaker T, Soreide J, Korner H . Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol. 2008; 18(1):31-50. DOI: 10.1016/j.suronc.2008.06.006. View